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Abstract Anticoagulants are a well known cause of drug-
induced liver injury (DILI). We recently encountered a
45-year-old male who developed DILI during treatment
with enoxaparin, a low-molecular-weight heparin
(LMWH), for dural venous thrombosis. The man received
enoxaparin 80 mg subcutaneously, twice daily. After 4
days, the patient was asymptomatic but he developed liver
aminotransferase elevations: AST 340 U/L and ALT
579 U/L. Investigation revealed an R ratio of 19.9 by day 5
and a Roussel Uclaf Causality Assessment Method score of
10, giving a high probable likelihood that enoxaparin was
the cause of hepatic injury. Enoxaparin was discontinued
on day 7, and 1 week later AST and ALT had decreased to
61 and 273 U/L, respectively. This case prompted a liter-
ature search and a review of the FDA Adverse Event
Reporting System (FAERS) database for the range of
hepatic adverse events (HAEs) associated with this class.
A MEDLINE/PubMed search was conducted using DILI
terms and cross-referenced with the anticoagulant classes.
A Freedom of Information Act (FOIA) request was also
made to identify adverse events (AEs) associated with
enoxaparin in FAERS. Case type, severity of outcome, and
demographic information were analyzed. Five publications
have reported DILI with enoxaparin. Trial data found
elevations in ALT [3 times the upper limit of normal
(ULN) for unfractionated heparins (UFH) and LMWH in 8
and 4–13 % of subjects, respectively. However, liver injury
in all cases was mild, self-limited, and asymptomatic. Our
FOIA request yielded 8336 adverse events related to
enoxaparin over a 14-year period (Jan 2000–Sept 2014).
Specific HAEs were found in 4 % of reports, but all were
described with other serious adverse events. The reported
outcomes of hospitalization (75 %), death (17 %), and life-
threatening medical events (5 %) were likely due to other
related serious adverse events such as hemorrhage (28 %)
and thrombocytopenia (11 %). We conclude that LMWH-
related liver injury is uncommon and reversible. The
mechanism of liver injury is not known, although an
idiosyncratic effect is postulated. Although the FAERS
database lists hepatic injury in 4 % of all enoxaparin-re-
lated AEs, it appears that serious outcomes are related to
non-hepatic events.
Key Points
Drug induced liver injury (DILI) associated with
low-molecular-weight heparins (LMWH) has a
hepatocellular pattern of injury, short latency (days
to weeks), rarely causes symptoms, and is not
associated with features of hypersensitivity.
The mechanism of liver injury is not known, though
an idiosyncratic direct toxic effect is postulated.
The FDA adverse event reporting system (FAERS)
database indicates that 4 % of all enoxaparin-related
adverse events involve hepatic injury; however, all
serious outcomes are related to non-hepatic events.
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Introduction
Unfractionated heparins (UFH) are naturally occurring
biologic molecules, widely used for anticoagulation [1].
Low-molecular-weight heparins (LMWH), the breakdown
product of UFH, have smaller and more uniform weights
than UFH allowing for a more predictable antithrombotic
effect [2]. LMWH are commonly utilized instead of UFH
because of their perceived improved safety profile [3].
When LMWH are used for the treatment and prophylaxis
of thromboembolic disorders, the most commonly reported
adverse effects from clinical trial data include major
bleeding (1.5–2 %) and thrombocytopenia (0.1 %) [4].
Another potentially important but less commonly reported
adverse effect of LMWH is drug-induced liver injury
(DILI), defined as aspartate aminotransferase (AST) and/or
alanine aminotransferase (ALT)[3 times the upper limit of
normal (ULN) [4].
Anticoagulant therapies of different classes have long
been identified as a cause of DILI [5–8]. The heparin
subclass, in particular, has the highest frequency of anti-
coagulant-associated hepatic adverse events (HAEs). UFH
are reported to cause liver injury in 8 % of patients, while
LMWH are implicated in 4–13 % of recipients [4, 9, 10].
In contrast, most other forms of anticoagulation are less
likely to cause DILI; only 1–3 % of patients on coumarins
(warfarin) [7, 11], 1.5–3 % on factor Xa inhibitors (fon-
daparinux, apixaban, rivaroxaban) [12–14], and 1.5–3 % of
patients on available direct thrombin inhibitors (dabiga-
tran) [15].
An important exception to this low risk of hepatotoxicity
from anticoagulants was seen with ximelagatran, one of the
first oral direct thrombin inhibitors. Ximelagatran was
associated with a far higher incidence of hepatic injury in
its long-term treatment trials, approaching 8 % of subjects
with ALT and AST [3 9 ULN, 4.7 % [5 9 ULN, and
1.9 %[10 9 ULN [16]. All of these percentages were far
higher than ALT elevations seen with the comparator [16].
Unlike DILI from other anticoagulants, ximelagatran-re-
lated hepatic damage had a longer latency and sometimes
progressed despite withdrawal of the medication [16]. As a
result, despite a promising benefit to prevent stoke, xime-
lagatran was never approved in the US [17] and was
eventually removed from the global marketplace due to the
risk of severe liver injury [18].
Since then, there has been increased attention paid to the
potential hepatoxicity of anticoagulants. However, cases of
HAEs from anticoagulants, like other drug classes, are
likely under-reported [19–21], and this appears to be the
case for both UFH and LMWH. Most published reports
have been limited to individual cases or small case series.
In this context, we recently encountered a case of severe
DILI attributed to the LMWH, enoxaparin. This prompted
us to perform a literature search for other published cases
of liver injury related to LMWH, and more specifically,
HAEs attributed to enoxaparin. In addition, we also
undertook a review of the FDA Adverse Event Reporting
System (FAERS) database to identify other post-marketing
cases of HAEs related to enoxaparin.
Case Report
A 45-year-old previously healthy African-American male
presented with several months of persistent right-sided
headaches and was found on admission to have a dural
venous thrombosis on MRI/MRV. He had taken no medi-
cations. He was initially started on a heparin drip and was
soon converted to the standard dose of enoxaparin at 1 mg/
kg, subcutaneously twice a day. At that time, his amino-
transferase values were normal (\40 U/L) with an AST
level of 29 U/L and ALT of 33 U/L. As seen in Table 1, all
other laboratory test values including albumin, bilirubin,
alkaline phosphatase, gamma-glutamyl transferase (GGT),
and international normalized ratio (INR) were also normal.
Four days after initiation of enoxaparin, the patient’s liver
aminotransferases were found to be elevated: AST 340 U/L
and ALT 579 U/L. They continued to increase over the
next 2 days, peaking on day 7 with an AST of 460 U/L and
ALT of 770 U/L. An R ratio, the initial step of the Roussel
Uclaf Causality Assessment Method (RUCAM), was cal-
culated from laboratory values on day 5 and found to be
19.9—consistent with a hepatocellular pattern of liver
injury [22]. The specifics of this calculation are shown in
Table 1.
Abdominal ultrasound with Doppler showed patent
hepatic and portal vessels with no steatosis. Acute viral
hepatitis serologies for hepatitis A, B, and C, as well as
Epstein-Barr virus and cytomegalovirus, were all found to
be negative. Autoantibodies including antinuclear anti-
body, anti-smooth muscle antibody, and anti-mitochondrial
antibody were also negative. The patient was not geno-
typed for any DILI biomarkers. The patient had no risk
factors for non-alcoholic fatty liver disease, no history of
alcohol abuse, no malnutrition, no recent exposures to
anyone with hepatic disease, and no episodes of severe
hypotension or congestive heart failure.
Although the patient remained asymptomatic and albu-
min, bilirubin, alkaline phosphatase, GGT, and INR all
continued to be normal, enoxaparin was discontinued on
day 7 and fondaparinux, a synthetic Xa inhibitor, was
started.
On day 13, 6 days after enoxaparin was discontinued
and fondaparinux was initiated, AST and ALT had
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decreased to 61 and 273 U/L, respectively. The patient
continued to be asymptomatic, and on day 22, the AST had
normalized to 29 U/L and the ALT had decreased to 70 U/
L. A RUCAM score was calculated to be 10 points, giving
a highly probable likelihood that enoxaparin was the cause
of hepatic injury.
Subsequently, an evaluation of the patient’s hyperco-
agulable state disclosed the finding of adenocarcinoma in
the large intestine for which he underwent appropriate
treatment. Fondaparinux was continued throughout the
duration of his colon cancer treatment without any effect
on liver-associated enzymes (LAEs). The patient provided
written informed consent for the publication of this case
report.
Literature Review of Enoxaparin and Other
Anticoagulants
Methods
A literature search was conducted using standard DILI
terms and cross-referenced with the anticoagulant classes
to identify cases of DILI by drug class. The standard DILI
terms used in the query prompt included hepatitis, liver
injury, hepatocellular injury, drug injury, hepatic injury,
and injury. Search terms for the heparin class included any
reports on UFH or the following three LMWH agents
approved by the FDA: enoxaparin, dalteparin, and tinza-
parin. HAEs related to coumarins or warfarin, as well as
DILI attributed to factor Xa inhibitors (specifically apixa-
ban and rivaroxaban) were also collected. Synthetic factor
Xa inhibitors such as fondaparinux, and marketed direct
thombin inhibitors like dabigatran were also queried.
Only papers printed in English that discussed DILI in
relation to these anticoagulants were reviewed. The search
dates were from 1975 to December 2014, which covers the
time since the first published case reports of anticoagulant-
related DILI [6, 8, 19]. The literature searches were based
on the following search engines: MEDLINE/Pubmed,
Livertox, and Google Scholar.
Results
Results of the literature search on each of the anticoagulants
are summarized in Table 2. Previous studies showed that
coumarins, factor Xa inhibitors, and recently approved direct
thrombin inhibitors rarely cause injury, with a frequency of
DILI ranging from 1 to 3 % based on clinical trial data [7,
11–14]. Liver injury was considered mild to moderate in
severity, self-limited, and largely asymptomatic. Discon-
tinuations of the suspected drug always led to resolution of
Table 1 Clinical laboratory
values of our patient
Variable Normal range Case report daya
0 1 5 6 7 13 22
INR 0.8–1.2 1.2 NA 1.1 1.1 1.0 1.1 1.2
AST (units/L) 3–34 29 NA 340 378 460 61 29
ALT (units/L) 15–41 33 NA 579 644 770 273 70
ALP (units/L) 38–126 78 NA 89 104 103 119 97
Bilirubin (mg/dL)
Total 0.02–1.3 0.3 NA 0.7 0.5 0.4 0.4 0.5
Direct 0.0–0.3 NA NA 0.10 0.10 0.10 NA NA
R ratiob 19.99
RUCAM scorec 10
ALP alkaline phosphatase, ALT alanine transaminase, AST aspartate transaminase, INR international nor-
malized ratio, NA not available, RUCAM Roussel Uclaf Causality Assessment Method, ULN upper limit of
normal
a Enoxaparin was initiated on day 1 and continued until day 7. Fondaparinux was initiated on day 7 and
continued
b R ratio: (ALT value 7 ALT ULN) 7 (Alk P value 7 Alk P ULN). R ratios of[5: hepatocellular injury,
\2: cholestatic injury, 2–5: mixed pattern of injury
c RUCAM score: Type of liver injury: hepatocellular; time of onset of the event: first exposure; time from
drug intake until reaction onset:\5 to[90 days (? 1 points); time from drug withdrawal until reaction
onset: B15 days (?1 point); alcohol risk factor: absent (0 points); age risk factor:\55 years (0 points);
course of reaction:[50 % improvement 8 days (?3 points); concomitant therapy: time to onset compatible
but known reaction (?2 points); exclusion of nondrug-related causes: ruled out (?2 points); previous
information: reaction labeled in the product’s characteristics (?2 points); response to re-administration:
positive (?3 points)
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Table 2 Drug-induced liver injury (DILI) characteristics summarized by anticoagulant drug classa
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the liver injury, and in some instances, aminotransferases
normalized despite continuation of treatment. In contrast,
UFH and LMWH caused higher rates of liver injury, 8 and
4–13 %, respectively, as noted in their package inserts
summarizing clinical trial results [9, 10].
A literature search specifically aimed at identifying
enoxaparin-related HAEs revealed a total of five published
reports [4, 23–26]. Table 3 provides the clinical details of
these cases, in addition to our patient. The series by Harrill
et al. describes the details of 12 subjects with enoxaparin-
induced liver injury [26]. In that trial, a total of 48 healthy
subjects were randomized to four groups and received
standard doses of subcutaneously administered UFH at
150 U/kg, enoxaparin at 1 mg/kg, dalteparin at 120 IU/kg,
or adomiparin 125 IU/kg for 5 days [26]. Daily liver tests
were drawn, and in 7 of the 12 men (58.3 %) who received
enoxaparin, elevations in AST and ALT were seen starting
on day 3. By day 6, all 12 subjects had aminotransferase
elevations above 3 9 ULN [26]. Six days after enoxaparin
was discontinued (day 12 of the study), all participants had
normalization of AST and ALT. Unfortunately, no follow
up data, specific patient demographic information, or
symptoms were provided in the study report.
Hui et al. described a 26-year-old female patient with
asymptomatic elevations in AST and ALT, 4 days after
starting enoxaparin [23]. The patient also started clar-
ithromycin and cefepime at the same time for the treatment
of pneumonia. The antibiotics were stopped after 1 week,
but enoxaparin was continued. The rises in aminotrans-
ferases along with alkaline phosphatase and GGT remained
stable for the duration of the first month. At the end of 60
days, enoxaparin was discontinued. One week later, there
was a fall in AST to 73 U/L, ALT to 152 U/L, and alkaline
phosphatase to 128 U/L. A percutaneous liver biopsy was
performed and showed preservation of acinar architecture,
with ballooning degeneration, and cytoplasmic swelling
mainly in zone 3 with focal changes in zone 2. Following
the liver biopsy, the patient was restarted on enoxaparin at
the same initial dose. Two weeks after this re-exposure,
similar abnormalities in LAEs were recorded. The patient
was switched to warfarin and liver tests returned to normal
over the next 2 months.
Table 2 continued







Not known 12 Hepatocellular pattern
of serum ALT and
AST elevations; can
be more than 3 9
ULN

























Not known; may be
idiosyncratic or
immunologic















after more than 35































ALT alanine transaminase, AST aspartate transaminase, LMWH low molecular weight heparin, ULN upper limit of normal
a References for each anticoagulant correspond with those in manuscript






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































17 Page 6 of 11 K. J. Hahn et al.
Another case reported by Baker et al. describes a
29-year-old female who developed an ALT of 400 U/L
after just two doses of enoxaparin [25]. The patient was
symptomatic with nausea and vomiting. Her symptoms and
liver enzyme elevations resolved quickly after enoxaparin
was discontinued. The other four publications were indi-
vidual case reports with varying amounts of information
regarding the hepatic event.
Other Low Molecular Weight Heparins (LMWH)
A review of the published literature regarding the two other
FDA-approved LMWH products, dalteparin and tinzaparin,
was also undertaken. Two published reports of liver injury
attributed to dalteparin were found [26, 27]. The clinical
details are summarized in Table 4. No cases of tinzaparin-
related HAEs were found in our literature search. In the
series by Harrill et al., 7 of 12 (58.3 %) healthy men given
dalteparin (120 IU/kg for 5 days) developed elevations in
AST and ALT of at least 3 9 ULN starting on days 6 and 7
[26]. However, by day 12, 1 week after dalteparin was
discontinued, these liver tests were seen to be declining
[26]. As with enoxaparin, no follow-up data, specific
patient demographics, or information on symptoms were
provided for this subgroup in the study. Similar to enoxa-
parin, dalteparin-related liver injury also appeared to be
mild in severity and reversible.
An individual case report of suspected dalteparin DILI
was described in a male with alpha-1 antitrypsin deficiency
(AATD) and normal baseline liver tests [27]. He developed
symptomatic elevations in aminotransferases 30 days after
starting the anticoagulant, with peak values of AST of
500 U/L and ALT of approximately 900 U/L. On day 42,
dalteparin was discontinued. A percutaneous liver biopsy
performed on day 43 showed condensation of the reticulum
network and expanded portal tracts mainly due to prolif-
erating bile ducts and infiltrates of inflammatory cells. In
addition, loss and necrosis of liver cells was described
mainly in zone 3. Hepatocytes showed ballooning and
cytoplasmic swelling; signs of intracellular cholestasis
were also found. At follow up 5 months later (day 191), the
patient’s AST and ALT had completely normalized. The
Table 4 Clinical details of dalteparin-associated liver injury in the literature
Study Age/gender Dose Symptoms and
onset






NA; 4 days AST: 320 U/L
ALT: 757 U/L





NA; 5 days AST: 241 U/L
ALT: 415 U/L
No No NA by individual; overall,





NA; 7 days AST: 149 U/L
ALT: 238 U/L
No No NA by individual; overall,





NA; 6 days AST: 131 U/L
ALT: 233 U/L
No No NA by individual; overall,





NA; 6 days AST: 202 U/L
ALT: 377 U/L
No No NA by individual; overall,





NA; 6 days AST: 155 U/L
ALT: 269 U/L
No No NA by individual; overall,





NA; 7 days AST: 96 U/L
ALT: 165 U/L
No No NA by individual; overall,














ALT alanine transaminase, AST aspartate transaminase, BID twice daily, F female, M male, NA not available, QD every day, SQ subcutaneous
a A percutaneous liver biopsy was performed on day 43. Dalteparin treatment had been discontinued on day 42. The biopsy showed condensation
of the reticulum network and expanded portal tracts due to proliferating bile ducts and infiltrates of inflammatory cells. Loss and necrosis of liver
cells, ballooning and cytoplasmic swelling, and signs of intracellular cholestasis were also seen. A second biopsy performed at follow-up visit 5
months after the initial biopsy showed almost complete remission of bile duct proliferation and no remaining signs of the presumed toxic and
cholestatic hepatitis
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authors were uncertain as to the mechanism of injury, but
theorized that adults with AATD may be more susceptible
to DILI [27].
In addition to case reports in the literature, we reviewed
the safety of LMWH compounds in their respective pre-
clinical development programs. None of the pre-clinical
toxicology reports, however, suggested that the liver was a
target for LMWH in either rodents or dogs [28]. In fact,
research in animals has demonstrated that heparins can
mitigate against liver injury in some rat models [28].
Nevertheless, animal toxicology studies are known to
correlate poorly with human DILI [20, 29]; as many as
40 % of known human hepatotoxins were not identified in
pre-clinical toxicology studies [20, 30].
Review of the FAERS Database for LMWH
Methods
In addition to our literature review, through a Freedom of
Information Act (FOIA) request, we performed an analysis
of the adverse hepatic events linked to enoxaparin con-
tained in the FAERS database for a 14-year period (January
2000–September 2014). HAEs were identified using the
following specific terms: hepatocellular injury, hepatitis,
hepatic injury, and liver abnormalities. Case type, severity
of outcome, and other demographic information were
reported through the FAERS protocol. Cases were classi-
fied as one of three types: expedited (serious, unexpected
events), non-expedited (non-urgent adverse events sub-
mitted by the manufacturer), or direct (non-urgent adverse
events submitted by healthcare providers or patients).
Outcome severity was categorized as resulting in either
death, hospitalization, a life-threatening medical event,
another serious important event or disability, or the need
for intervention. Dosage information for enoxaparin was
divided into B120 or C120 mg given subcutaneously per
day. Duration of usage was categorized as\2 or[2 weeks.
Concomitant polypharmacy was defined as greater than or
equal to four medications in addition to enoxaparin. HAEs
were analyzed using logistic regression and frequency
tabulations [31].
Results
Our enoxaparin FOIA request yielded 8336 adverse events
reported from January 2000 through September 2014. The
number of patients with specific HAEs was 311 (3.7 % of
the total). Of those, 281 (93 %) were classified as expe-
dited reports, 9 (3 %) as non-expedited, and 13 (4 %) as
direct. The majority of cases were reported from France
(97 %). A slight majority of HAEs occurred in women
(51 %) and the mean age of all patients was 56.7 years. For
these 311 patients, the most commonly reported outcomes
were hospitalization (75 %), death (17 %), and life-
threatening medical events (5 %). However, all HAEs were
reported as one of several concomitant adverse events, and
were not reported as isolated adverse events. Since we were
not provided with any individual case details, we were
unable to correlate the reported outcomes with the specific
occurrence of a HAE.
Overall, the most commonly reported AEs were hem-
orrhage in 28 % and thrombocytopenia in 11 %. These
serious adverse events likely had a more important bearing
on the need for hospitalization, death, and other serious
medical outcomes than did any of the HAEs. In addition,
the clinical indications for anticoagulation were also not
available for our review. However, given the high rate of
bleeding reported, it would appear that death and other
serious outcomes were more likely to be related to these
common AEs and other patient comorbidities. Patients on
higher doses of enoxaparin were more likely to have seri-
ous outcomes or death (OR 2.29; 95 % CI 0.90–5.82).
Similarly, longer duration of therapy increased the odds of
hospitalization (OR 1.30; 95 % CI 0.36–4.64). Polyphar-
macy was also associated with a slightly higher chance of
death among these patients (OR 1.10; 95 % CI 0.55–2.20).
Discussion
DILI caused by anticoagulants dates back more than 40
years [5, 25]. Hepatotoxicity attributed to the heparin
subclass was first described in 1975 [5, 25, 32]. The three
LMWH approved in the US to date include enoxaparin
(1993), dalteparin (1994), and tinzaparin (2000) [10, 33,
34]. HAEs caused by heparin have been well documented
[4, 35]. The hepatic injury pattern caused by both UFH and
LWMH appears similar, with mostly asymptomatic ele-
vations in aminotransferases without concomitant changes
in bilirubin. Most patients, like ours, have aminotransferase
elevations in the first week of usage and normalization of
LAEs quickly follows discontinuation. The majority of
anticoagulant-related DILI have a hepatocellular pattern of
injury. The one exception is the case reported by Hui et al.,
which showed a mixed pattern but was also confounded by
the concomitant use of antibiotics [23]. Coumarins typi-
cally produce cholestatic injury [11, 36]. Regardless of the
agent or the injury pattern, anticoagulant-associated DILI is
generally mild.
The exception among anticoagulant-associated DILI
remains ximelagatran, an oral direct thrombin inhibitor,
which was found to cause severe hepatic injury (with
several cases meeting Hy’s Law criteria) in longer-term
clinical trials [16]. Subsequent pharmacogenomic studies
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[37] identified a genetic predisposition for ximelagatran-
related DILI. While the exact cause of injury remains
unknown, patients with HLA-DRB1*07 and DQA1*02
genotypes have an increased risk of developing serum ALT
elevations, possibly through an activation of the host’s
immune response [37–39]. To our knowledge, such HLA
or other genetic predispositions have not been evaluated in
other anticoagulant classes.
With enoxaparin, instances of DILI often occur within 1
week of starting therapy, representing a very short latency
period. Patients are generally asymptomatic and without
hypersensitivity features such as fever, skin rash, or eosi-
nophilia [4]. Given the frequency of LMWH-related ALT
elevations, in the absence of a clear immunoallergic
mechanism, it is believed that heparins may have a direct
toxic effect on the liver, as suggested by Harrill et al. [26].
The histopathology from single cases receiving enoxaparin
and dalteparin point to the presence of a predominantly
hepatocellular form of injury [23]. The absence of serum
plasma cells or eosinophils argue against an immune/al-
lergy etiology; however, the number of cases with liver
biopsies is too small to draw any firm conclusions [23].
A recent study focusing on biomarkers of DILI further
supports the possibility that a direct toxic effect on the
hepatocyte causes the hepatocellular injury reported with
enoxaparin [26]. Heparins have not been shown to form
reactive metabolites [5]. Harrill and colleagues have pro-
posed that leakage of specific hepatic intracellular
biomarkers, such as miR-122, into the serum after enoxa-
parin exposure suggests that this agent causes transient
hepatocyte necrosis [23, 24, 26]. In addition, research has
shown an increase in HMGB1, a protein associated with
damage in necrotic cells, following the usage of heparin
[26]. The peaking of both miR-122 and HMGB1 in the
days following heparin usage is consistent with the belief
that LMWH such as enoxaparin directly injure the hepa-
tocyte, resulting in necrosis [26]. Such direct injury is
confirmed by the frequency of enoxaparin-related ALT and
AST as shown by Harrill et al., where more than 50 % of
healthy subjects started on enoxaparin developed DILI
within 1 week and all were affected by day 12 [26]. As the
frequency and dosing of enoxaparin increases, so too does
the magnitude of aminotransferase elevations [40, 41],
raising the possibility of dose-related injury.
For heparins, hepatoxicity is the most frequently
reported adverse event. The information compiled in the
National Library of Medicine’s LiverTox database [42]
notes that liver injury is responsible for 8 % of adverse
events from UFH and 4–13 % from LMWH based on
clinical trial data [9, 10]. A review of the FAERS database
further corroborates this frequency, with approximately
4 % of all enoxaparin-related adverse events involving the
liver. Liver toxicity, however, was not reported to be an
isolated AE in FAERS, as HAEs were always associated
with other, more serious events. The majority of reported
LMWH-related HAEs in FAERS were reported from
France, however the reason for this is uncertain.
While higher dosage and longer duration of enoxaparin
were more likely to lead to hospitalization and/or death,
these serious outcomes are likely the result of hemorrhage
or other severe AEs coupled with the underlying patient
comorbidities requiring anticoagulation. The relatively
small proportion of patients listed as having HAEs, com-
bined with the generally mild clinical course and reversible
nature of DILI described in the published literature, sug-
gests that the HAEs by themselves are unlikely to have
contributed significantly to the morbidity and mortality
reported in FAERS. Similarly, the polypharmacy associ-
ated with a higher risk of death in patients on enoxaparin
also likely reflects the numerous comorbidities that affect
such patients.
Our case is consistent with the clinical signature that has
emerged for enoxaparin liver injury as reported in previous
case reports. Characteristically, enoxaparin DILI has a
short latency and rapid reversibility, without accompanying
hypersensitivity symptoms such as fever, rash, or
eosinophilia. In our patient, aminotransferase elevations
peaked by day 7 and began to normalize quickly thereafter.
While the peak values were higher than those in other
published reports, liver injury had completely resolved
after the drug was discontinued. Of note, the fondaparinux
that replaced enoxaparin on day 7 was found to have no
cross reactivity, as liver tests remained normal. Other novel
oral anticoagulants may also be good alternatives in
treatment of venous thrombosis, as they to do not require a
‘bridge therapy’ and have lower rates of HAE [43, 44].
Given that a similar hepatic pattern of injury is associated
with UFH, heparin-induced liver injury is presumed to be a
class effect.
While FAERS is extremely useful in identifying
potential new safety concerns, the reports submitted to the
database are voluntary and do not require proven causal
relationships between product and event [45]. Specifically,
few reports have sufficient clinical and laboratory data to
fully adjudicate an event. In addition, individual patient
data and outcomes are not always available. This was the
case for enoxaparin. Although the FAERS database can be
supportive of the published literature for many individual
agents, it cannot be used to calculate incidence data of an
adverse event, such as DILI. Furthermore, the cause of the
specific outcomes of hospitalization and death reported in
relationship to enoxaparin cannot be definitively deter-
mined without an assessment of the complete medical
record, for which we did not have access. More than likely,
however, serious outcomes related to the underlying dis-
eases requiring anticoagulation were the result of
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hemorrhage, thrombocytopenia, or other serious compli-
cations, rather than any of the hepatic AEs.
Conclusion
A review of the published literature of adverse events
associated with enoxaparin indicates that up to 13 % of
reported AEs involve the liver [45]. The FAERS database
estimates a frequency of 4 % for HAEs, although these
were always associated with other causes of morbidity and
mortality, such as hemorrhage and thrombocytopenia.
Enoxaparin-related liver injury has a short latency of
approximately 1 week, and patients are usually asymp-
tomatic without hypersensitivity features. The serious
outcomes reported in FAERS, such as the need for hospi-
talization (75 %) and death (17 %), are most likely the
result of the non-hepatic AEs. Similarly, the observation
that higher dosages and longer duration of enoxaparin
therapy, along with polypharmacy, are associated with
such adverse outcomes are also more likely to be the result
of non-hepatic causes.
In comparison with other forms of anticoagulation,
enoxaparin-induced liver injury is similar to what has been
reported with UFHs and several of the newer classes of
anticoagulants. Severe DILI, however, appears to be
unusual.
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